Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01340300 · ClinicalTrials.gov registry record · Phase 2
Exercise and Metformin in Colorectal and Breast Cancer Survivors
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 139
- Enrollment target
NCT01340300 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 139 participants.
The verdict
NCT01340300, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 139 participants
- Enrollment target
Study Summary
Metformin is a medication that is commonly used in the treatment of diabetes. Recently small studies in cancer patients without diabetes suggest that metformin may benefit in lowering insulin levels. In those studies of patients with cancer but not diabetes, glucose (or sugar) levels in the blood are generally no lowered. Insulin and insulin-like growth factors affect the growth of cancer cells. This randomized study will compare different interventions; exercise, exercise and metformin, metformin alone, or a control arm. The investigators are not directly testing how either exercise or metformin affects your disease. The investigators are testing how they affect insulin levels in your body as well as other blood markers. The investigators believe that these blood tests may either be related to cancer recurrences or be an early sign of cancer recurrences and they are testing how both exercise and metformin may change those markers.
Interventions
- DRUG Metformin
- BEHAVIORAL Exercise training
- OTHER Educational information
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2011-05 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01340300
The ClinicalTrials.gov registry entry for NCT01340300 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Metformin is the first listed.
NCT01340300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01340300 about?
NCT01340300 is a clinical study titled "Exercise and Metformin in Colorectal and Breast Cancer Survivors". Metformin is a medication that is commonly used in the treatment of diabetes. Recently small studies in cancer patients without diabetes suggest that metformin may benefit in lowering insulin levels. In those studies of patients with cancer but not diabetes, glucose (or sugar) levels in the blood ar...
What is the current status of trial NCT01340300?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 139 participants. The study started on 2011-05. Estimated completion is 2017-12.
What interventions are being tested in trial NCT01340300?
The interventions under investigation include: Metformin (DRUG), Exercise training (BEHAVIORAL), Educational information (OTHER).
Who is sponsoring clinical trial NCT01340300?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.